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Background: As a novel candidate metastasis suppressor gene, Nasopharyngeal carcinoma-associated gene 6 (NGX6)
is involved in cellular growth, cell cycle progression and tumor angiogenesis. Previous studies have shown that NGX6
gene is down-regulated in colorectal cancer (CRC). However, little is known about its transcriptional regulation.
Results: We defined the minimal promoter of NGX6 gene in a 186-bp region (from-86 to +100) through mutation
construct methods and luciferase assays. Results from Electrophoretic mobility shift assays (EMSA) and Chromatin
immunoprecipitation (ChIP) revealed that Early growth response gene 1 (Egr-1) binds to the Sp1/Egr-1 overlapping
site of NGX6 minimal promoter. Overexpression of Egr-1 increased the promoter activity and mRNA level of NGX6
gene; while knock-down of endogenous Egr-1 decreased mRNA expression of NGX6 gene.
Conclusion: These results demonstrate that Egr-1 regulates NGX6 gene transcription through an overlapping
Sp1/Egr-1 binding site as a positive regulator of NGX6 gene.Background
Nasopharyngeal carcinoma associated gene 6 (NGX6) was
located on chromosome 9p21-22 [1]. In previous studies,
results from various analysis including RT-PCR, Dot
hybridization and Northern blot showed that the mRNA
levels of NGX6 were significantly lower in colorectal
carcinoma tissues with lymph node or distant metastasis
than that in paracancerous tissues [2]. And its mRNA
expression level in nasopharyngeal carcinoma tissues was
also lower than that in normal nasopharyngeal epithelial
tissues [3]. Some studies demonstrated that NGX6 may
play an important role in EGFR/K-ras/JNK/c-Jun/cyclinD1
signal pathway and Wnt/β-catenin signal pathway [4-6].
Overexpression of NGX6 gene in colon cancer cells was
able to inhibit cell growth and cell cycle progression from
G1 to S phase [7,8]. As a transmembrane protein, NGX6
protein has been demonstrated to regulate the transduction* Correspondence: liuminji1982@163.com; ssr-35403@163.com
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reproduction in any medium, provided the orof extracellular signals into cytoplasm and nucleus through
binding with the membrane cytoskeleton-organizing pro-
tein ezrin by its cytoplasmic domain. And it is also involved
in cellular adhesion, invasion, motility and metastasis
[9,10]. But its transcriptional regulation remains unknown.
We have previously reported a region spanning from −159
to +276 bp as the proximal promoter of NGX6 gene [11].
In this report, we defined the minimal promoter of NGX6
gene in a 186-bp region, and explored the role of Egr-1 in
positive regulating of NGX6 expression in colon cancer
cells. These results will help to further understand and un-
cover the bio-functions of NGX6 gene involved in the
pathogenesis of colorectal carcinoma.Methods
Cell culture
The human colon carcinoma cell lines, HT-29, SW480 and
SW620, were from American Type Culture Collection
(ATCC, Rockville, MD). COS7 cells were provided by the
Cancer Research Institute, Xiangya School of Medicine,
Central South University (Human, P.R. China). All cells
were cultured in RPMI1640 medium containing 10%
heat-inactivated fetal bovine serum (FBS) and incubated at
37°C in a humidified incubator with 5% CO2.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Potential binding sites of transcription factors within the
promoter region spanning from −86 to +100 bp of NGX6
gene were analyzed by MatInspector Professional (http://
www.genomatix.de).
Luciferase- reporter vectors and assay
In order to define the minimal promoter of NGX6, a
series of 5’ or 3’ deletion fragments generated from the
proximal promoter construct pGL3-159/+276 were suc-
cessfully amplified by PCR using the primers listed in
Table 1. All the primers included 9-bp noncomplementary
extensions capable of generating KpnI, HindIII or NheI
restriction sites. These deletion fragments were cleaved,
gel-purified and cloned into pGL3-enhancer vector
(Promega). Five promoter plasmids (pGL3 -159/+100,
pGL3 + 100/+276, pGL3 -159/-86, pGL3 -86/+12 and
pGL3 + 12/+100) were verified by restriction enzyme
cutting and sequencing.
Cells were seeded at 5 × 105 cells/well and cultured in
12-well plates for 24 h prior to transfection. The cells
were transfected with 1 μg of various NGX6 promoter
constructs, pGL3-control plasmid, or pGL3-enhancer plas-
mid by Lipofectamine 2000 reagent (Invitrogen) according
to manufacturer’s instructions. To control transfection
efficiency, cells were co-transfected with 0.5 μg SV40 β-
galactosidase vector per well. 48 h after transfection, the
cell lysates were prepared and luciferase activity was mea-
sured by luciferase assay kit (Promega). β-galactosidase
activity was also quantified using the β-galactosidase En-
zyme Assay System (Promega). Experiments were repeated
at least three times with three replicates per sample.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein was prepared by using NR-PER nuclear
and cytoplasmic extraction reagents (Pierce Biotechnol-
ogy, Rockville, IL). Then nuclear supernatants were
collected and stored at −80°C until used. Protein con-




pGL3 + 100/+276 Forward: 5′- AAAGGTACCGCCTGAACTCCTACCCA-3'
Reverse: 5′- AAAGCTAGCGGATTGGGATAGGACGAG-3'
pGL3-159/-86 Forward: 5′- AAAGGTACCTGTGCTTGGGGTGAGAAA-3'
Reverse: 5′- AAAAAGCTTTTAGTCCTGCTGGGCTTC-3'
pGL3-86/+12 Forward: 5′- AAAGGTACCTCCTCGAAGCCCAGCAG -3'
Reverse: 5′- AAAAAGCTTACTTGACGTCGGCGTGAC-3'
pGL3 + 12/+100 Forward: 5′- AAAGGTACCGCCGACGTCAAGTCGAG-3'
Reverse: 5′-AAAAAGCTTGGGACCTGGGTAGGAGTTC-3'(Pierce Biotechnology, Rochville, IL). And the following
oligonucleotides and their complementary strands were
synthesized and polyacrylamide gel electrophoresis
(PAGE)-purified by Songan: NGX6 (−54/-39) 5′-GTAG
GGCGGGGGCGGGCTTTACT-3′ (in which the G/C-
rich sequences shown in italics are potential binding
sites for the transcription factors for Egr-1 and Sp1).
According to the manufacturer’s instructions of light-
shift chemiluminescent EMSA Kit (Pierce), 10 ug nuclear
protein extracts were incubated with 50 fmol of biotin la-
beled oligonucleotides for 20 min at room temperature
(20°C ~ 25°C). In competition experiments, prior to the
addition of the labeled oligonucleotides nuclear extracts
were incubated for 10 min with excess unlabeled oligonu-
cleotides. The reaction mixtures were then resolved on 6%
polyacrylamide gel in 0.5 × TBE. Then the binding reac-
tions were transferred to nylon membrane and crosslink-
ing was performed with a hand-held UV lamp equipped
with 254 nm bulbs. Finally, the biotin-DNA was detected
by chemiluminescence.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed by using a kit from Upstate
Biotechnology. HT-29 cells were crosslinked by ‘ing 1%
formaldehyde in cell culture medium for 10 min at room
temperature, followed by adding glycine to end the process.
The cross-linked chromatin was sonicated to yield frag-
ments of 200 to 1000 bp. Soluble chromatin was then clari-
fied by centrifugation for 10 min at 14000 rpm at 4°C, and
1% of the supernatant was saved as input. Diluted soluble
chromatin fragments were precleared with protein G agar-
ose to discard nonspecifically bound chromatin fragments,
then immunoprecipitated with antibodies against Sp1(07–
645) (Upstate Biotechnology) or Egr-1(588) (Santa Cruz
Biotechnology) overnight at 4°C. Immunocomplexes
were captured on the ssDNA/protein G-agarose slurry,
and washed sequentially with low-salt wash buffer, high-
salt wash buffer and LiCI wash buffer, followed by two
final washes with TE buffer. After washing, the immu-
nocomplexes were eluted by incubation for 15 min at
25°C with 200 μl of elution buffer, and reversed for 6 h
at 65°C. The DNA fragments were extracted with
phenol/chloroform and precipitated with ethanol. The
immunoprecipitated DNA samples were analyzed by
PCR using the primer pair: (forward) 5′-AAAGGTAC
CTGTGCTTGGGGTGAGAAA-3′ and (reverse) 5′-AA
AGCTAGCGGGACCTGGGTAGGAGTT-3′. PCR was
carried out for 35 cycles by using a step cycle of 95°C
for 30 sec, 55°C for 50 sec, 72°C for 1 min, and followed
by 72°C for 10 min. A 259 bp product was detected from
the reaction. As a negative control for PCR, water was
added instead of the immunoprecipitated chromatin frag-
ments. The PCR products were analyzed by electrophor-
esis on a 5% agarose gal.
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To construct wild type Egr-1 expression vector, Egr-1 gene
cDNA was amplified by PCR method using human fetal
brain cDNA library as template. According to the sequence
of Egr-1 gene (NM_001964) obtained from GeneBank, the
following primers with EcoRI and XhoI restriction enzyme
sites were used: Egr-1 (forward) 5′-TTTGAATTCAGG
ATGGCCGCGGCCAAG-3′ and (reverse) 5′-CACCTC
GAGTTAGCAAATTTCAATTGTC-3′ (restriction sites
underlined). After an initial denaturation step at 94°C
for 10 min, the PCR was carried out for 38 cycles at 94°C
for 30 sec, 58°C for 50 sec, 72°C for 2 min, and followed
by 72°C for 10 min. The PCR fragments were purified and
subcloned into EcoRI/XhoI-digested pCMV-HA vector,
then transformed into competent JM109 cells. Positive
clones were sequenced to verify the correct inserts, and
then named as pCMV-HA/Egr-1.
siRNA target to Egr-1
Egr-1 oligo small interfering RNA (siRNA) (5'-CCAUG
GACAACUACCCUAA[dT][dT]-3') and a negative con-
trol siRNA (5'-ACUUACGAGUGACAGUAGA[dT][dT]-
3') were purchased from GenePharma. For siRNA trans-
fection, SW480 cells were plated overnight in 6-well dish
at a density of 1 × 106 cells/per well. They were transiently
transfected with 100 nM siRNA using lipofectamine 2000
transfection reagent as described by the manufacturer
(Invitrogen). The cell lysates were harvested 2 days after
transfection. The total RNA from SW480 cells was
isolated with the RNeasy Mini Kit (Qiagen, Hilden,
Germany). Then Egr-1 expression and NGX6 expres-
sion were evaluated by RT–PCR or Real-time quantita-
tive PCR.
RT-PCR and Real-time quantitative PCR
Total RNA from harvested cells was isolated using Trizol
reagent (Invitrogen) and then treated with DNaseI (Roche)
to eliminate possible DNA contamination. RNA was quan-
tified by optical density (A260) and stored at −80°C until
used. cDNA was prepared using Reverse Transcription
System (Promega).
2 μl single-stranded cDNA was amplified by PCR using
NGX6-specific primers primers and glyceraldehide-3-
phosphate dehydrogenase (GAPDH) primers. The GAPDH
primers were added to the PCR at the end of the tenth
cycle as control experiments. RT-PCR products were ana-
lyzed by electrophoresis on a 5% agarose gal.
Real-time quantitative PCR was performed using SYBR®
Premix Ex Taq™ (TaKaRa, Dalian, China) according to
manufacturer’s recommendations. 96 wells plates were
used on BIO-RAD IQ™5 thermocycler. Cycling conditions
were as follows: an initial step at 95°C 5 min for enzyme
activation, followed by 40 cycles alternation of 10 sec at
95°C, 15 sec at 54°C, 30 sec at 72°C and a finaldissociation step. Obtained Ct values were normalized
against GAPDH. Relative gene-expression was deter-
mined by using the △Ct method [12]. The primers were
used in RT-PCR and Real-time qPCR were as follows:
NGX6 forward (5'-AGAACCGCCATCCCTT-3'), NGX6
reverse (5'-CACCTCGTGAGTCAAGCA-3'), Egr-1 for-
ward (5′-CACGAACGCCCTTACGCT-3'), Egr-1 reverse
(5′-CATCGCTCCTGGCAAACT-3'), GAPDH forward (5'-
AGGTCGGAGTCAACGGATTTG-3'), GAPDH reverse
(5'-GTGATGGCATGGACTGTGGT-3').
Data presentation and statistics
Promoter/reporter transient transfections were repeated
at least three times and results were expressed as mean ±
SE. Statistical differences was determined using the Stu-
dent’s t-Test. Statistical significance was determined at the
p < 0.05 level. The EMSA and ChIP experiments were re-
peated at least three times and one representative result
was shown for each set of experiments.
Results
Identification of NGX6 minimal promoter (−86/+100)
In order to define the minimal promoter of NGX6 gene,
five progressive 5' ends deletion constructs were generated
from the full-length promoter construct pGL3 -159/+276
(Figure 1A). Plasmid pGL3 -159/+276, pGL3 -159/+100,
pGL3 + 100/+276, pGL3 -159/-86, pGL3 -86/+12 and
pGL3 + 12/+100 were transiently transfected into COS7
and HT-29 cells, respectively. The luciferase activity
driven by NGX6 promoter constructs was measured
after transfection for 48 h. Luciferase expression levels
were corrected for variable transfection efficiencies by
cotransfection with β-galactosidase plasmid. As shown
in Figure 1B, three constructs, pGL3 -159/+100, pGL3
-86/+12 and pGL3 + 12/+100 showed the same high
luciferase expression as the full-length promoter
construct pGL3 -159/+276, whereas luciferase expres-
sion in pGL3 + 100/+276 and pGL3 -159/-86 transfected
cells was extremely low as pGL3-enhancer. These
results indicated that a 186-bp fragment spanning
positions −86 to +100 bp is required for the basal trans-
criptional activity of the NGX6 promoter.
Transcription factor Sp1 and Egr-1 bind to an overlapping
Sp1/Egr-1 binding motif in the NGX6 minimal promoter
A region spanning −86 to +100 bp of NGX6 minimal pro-
moter was performed with MatInspector Professional pro-
gram. Some critical putative binding sites were predicted
in this region, including the binding site for Sp1 (−17/+5),
two NF-Y binding sites (−78/-56 and −36/-18) and a Sp1/
Egr-1 overlapping site (−54/-39) (Figure 2). To identify the
binding of transcription factor(s) to this putative overlap-
ping binding site within NGX6 promoter, EMSA and
ChIP were performed. EMSA assay was conducted using a
Figure 1 Identification of NGX6 minimal promoter (−86/+100).
(A) Schematic illustration of deletion constructs of NGX6 proximal
promoter pGL3-159/+276. (B) Luciferase activity of the deleted
constructs in COS7 and HT-29 cells. pGL3-control, pGL3-enhancer
and NGX6 promoter constructs were transfected into COS7 and
HT-29 cells, respectively. All of the vectors were cotransfected with
β-galactosidase vector for normalizing transfection efficiency.
Luciferase activities were analyzed 48 hours post transfection. Data
are expressed as mean ± SE of three independent experiments.
Figure 3 Transcription factor Sp1 and Egr-1 bind specifically to
the Sp1/Egr-1 overlapping site in NGX6 minimal promoter.
(A) Electrophoretic mobility shift assay demonstrating complex
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to −39 bp region. As shown in Figure 3A, three DNA
protein complexes were detected after incubate the probe
with nuclear extract from HT-29 cells. The complex
formation was fully suppressed by the addition of a
100-fold molar excess of unlabeled wild type −54 to
−39 bp oligonucleotide probe. This suppression was not
observed when 100-fold molar excess of unlabeledFigure 2 Bioinformatics analysis of putative cis-acting elements
in NGX6 minimal promoter region −86/+100 by MatInspector
program. A series of results were predicted, including Sp1 binding
site(−17/+5), two NF-Y binding sites (−78/-56 and −36/-18) and a
Sp1/Egr-1 overlapping site (−54/-39). The genomic sequence
number 35819222 of NGX6 gene is defined as +1.mutated type −54 to −39 bp oligonucleotide probe was
added as competitor. These results indicated that the Sp1/
Egr-1 binding site at −54 to −39 bp is specific. To investi-
gate whether transcription factor Sp1 and Egr-1 interacts
with NGX6 minimal promoter through their specific
binding sites in vivo, ChIP assay was performed. As shown
in Figure 3B, with the DNA samples immunoprecipitated
in HT-29 cells by rabbit polyclonal antibodies against Sp1
and Egr-1 respectively as templates, a 259 bp DNA frag-
ment of NGX6 promoter could be amplified. These re-
sults further showed that transcription factor Sp1 and
Egr-1 specifically bind to NGX6 minimal promoter.
Role of the transcription factor Egr-1 in the regulation of
NGX6 promoter activity
In order to detect the effects of transcriptional factor Egr-1
on the promoter activity of NGX6 gene, we constructed
plasmid pCMV-HA/Egr-1. The plasmid was confirmed by
enzyme cutting (Figure 4A) and sequencing (Figure 4B).
SW620 cells were transfected with 0.5 μg NGX6 promoter
constructs pGL3 -86/+12, 0.5 μg SV40 β-galactosidase vec-
tor and various amount of pCMV-HA/Egr-1. As shown in
Figure 5, overexpression of Egr-1 increased the promoter
activity of pGL3-86/+12 in SW620 cells. Similar results
were observed in HT-29 and SW480 cells (data no shown).formation between the G/C-rich, potential Sp1/Egr-1 binding
domain of NGX6 gene promoter in HT-29 cells. Oligonucleotides
−54/-39 containing a Sp1/Egr-1 overlapping site was incubated with
10-μg nuclear extracts of HT-29 cells in EMSA. For competition assay,
5-pmol of unlabeled wild-type or mutated oligonucleotide was
added to the reaction mixture, before the addition of labeled
probes. (B) ChIP assay of the NGX6 promoter at the Sp1/Egr-1
overlapping binding site. Crosslinked chromation was sheared with
nine 10-sec pulses at 10-sec intervals. Immunoprecipitation of
chromatin fragments were carried out with anti-Sp1, and anti-Egr-1,
respectively. Rabbit IgG was used as a negative control and Input
was used as a positive control. After de-crosslinking, the purified
DNA samples were analyzed by PCR. water (a reaction without any
DNA) were used as a negative control for PCR.
Figure 4 Identification of pCMV-HA/Egr-1 vector. (A) verfication of pCMV-HA/Egr-1 by enzyme cutting. Lane 1: DL 2000 molecular mass
marker; lane 2 and 3: enzyme cutting of pCMV-HA/Egr-1 with EcoRI and XhoI. (B) The results of sequencing of pCMV-HA/Egr-1. The reverse primer
was presented.
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positive regulatory element for NGX6 gene.
Requirement of Egr-1 for induction of NGX6 expression
To investigate whether Egr-1 was required for induction
of NGX6 gene expression, pCMV-HA/Egr-1 was transi-
ently transfected into SW620 cells, and pCMV-HA was
used as a negative control. 48 h after transfection, mRNA
was isolated from the cells. NGX6 mRNA expression was
detected by RT-PCR (Figure 6A) and Real-time quantita-
tive PCR (Figure 6B). These results indicated that com-
pared to overexpression of the control vector pCMA-HA,
NGX6 mRNA level was increased when Egr-1 was overex-
pressed in SW620 cells.
To investigate the role of endogenous Egr-1 in regula-
tion of NGX6 expression, siRNA technology which small
DNA inserts encoding short hairpin RNA against Egr-1
expression was used. SW480 cells were transfected withFigure 5 Transcriptional factor Egr-1 increases NGX6 promoter
activity in SW620 cells. 0.5 μg pGL3-86/+12 vector was
cotransfected with 0.5 μg SV40 β-galactosidase vector and various
amount pCMV-HA/Egr-1 into SW620 cells by Lipofectamine 2000
Reagent. Luciferase activity was measured in cell extracts after
transfection for 48 h. Then β-galactosidase was used for for
normalizing transfection efficiency. Data are expressed as mean ± SE
of three independent experiments.siRNA-Egr-1 or siRNA-control, respectively. 48 h after
transfection, mRNA was isolated from harvested cells.
RT-PCR (Figure 7A) and Real-time quantitative PCR
(Figure 7B) revealed that compared with siRNA-control,
transfection with siRNA-Egr-1 reduced the expression
levels NGX6 mRNA. Taken together, these results indi-
cated that Egr-1 is required for NGX6 mRNA expression.
Discussion
NGX6 (genebank accession number AF188239), a novel
candidate metastasis suppressor gene, was cloned by a
location candidate cloning strategy. Its function is asso-
ciated with colorectal carcinoma occurrence and devel-
opment. Previous study has indicated that NGX6 was
decreased or undetectable in colorectal carcinoma and
involved in cellular growth, cell cycle progression and
tumor angiogenesis. However, little is known about the
transcriptional regulation of NGX6 gene.
Bioinformatics analysis indicated that no canonical
TATA boxes were found in NGX6 promoter, while two
CAAT boxes, a GpG island and putative transcription
binding sites for Sp1, Egr-1, NF-Y etc. were discovered
[13]. In this report, using various promoter deletion con-
structs, the minimal promoter of NGX6 gene was de-
fined in a −86 to +100 bp region, which is the shortest
promoter identified so far in the regulatory region of
NGX6 gene. The results of MatInspector showed that
this region contained an overlapping Sp1/Egr-1 GC-rich
motif for the binding of the zinc finger transcription fac-
tors Egr-1 and Sp1. EMSA along with ChIP assays con-
firmed a specific Sp1/Egr-1 overlapping site spanning
from −54 to −39 bp in NGX6 minimal promoter. Similar
Sp1/Egr-1 overlapping binding sites have been shown to
play a critical role in the expression of some genes, such
as TF, NDRG1 and PDGF-A [14-16]. The regulation of
transcription by these two transcription factors has been
shown to be complex: in some genes the two factors are
synergistic, whereas in other systems the factors appear
Figure 6 Overexpression of Egr-1 down-regulated the mRNA
Expression level of NGX6 gene in SW620 cells. (A) mRNA
expression of NGX6 was assayed by reverse transcription ploymerase
chain reaction (RT-PCR). (B) mRNA expression level of NGX6 gene
and Egr-1 were examined by Real-Time quantitative PCR. Results are
presented as mean ± SE (n = 3). pCMV-HA was used as negative
control. Statistically significant differnces from control levels are
indicated by *(P < 0.05).
Figure 7 Knockdown of endogenous Egr-1 decreased the
mRNA Expression level of NGX6 gene in SW480 cells. (A)
Detection of NGX6 mRNA expression by RT-PCR. And the PCR
products were analyzed by electrophoresis on a 5% agarose gal.
(B) mRNA expression level of NGX6 and Egr-1 were examined by
Real-Time quantitative PCR. Results are presented as mean ± SE
(n = 3). siRNA-control was used as negative control. Statistically
significant differnces from control levels are indicated by *(P < 0.05).
Liu et al. BMC Molecular Biology 2014, 15:14 Page 6 of 7
http://www.biomedcentral.com/1471-2199/15/14to compete [17,18]. Egr-1 encodes a nuclear phospho-
protein that binds to the GC-rich sequence 5'-GCG
GGGGCG-3' and regulates transcription of target gene
through the GC-rich consensus sequence [19]. Egr-1 ex-
pression had been found to be either decreased or un-
detectable in nasopharyngeal carcinoma and colorectal
carcinoma [20,21]. Various studies have indicated Egr-1
is involved in regulation of cell proliferation and may
have tumor suppressive functions [22,23]. In our experi-
ment, immunohistochemical staining of Egr-1 showed
weaker staining in metastatic tissue in comparison to
non-metastatic tissue in a colorectal tissue microarray.
RT-PCR and Western Blot also confirmed that Egr-1
expression level in SW620 cells is lower than that in
SW480 cells (data not shown). Therefore, we hypothesize
that Egr-1 regulate the expression of NGX6 gene in colo-
rectal cancer as a tumor suppressor gene. In our study,
overexpression of Egr-1 increased the activity of NGX6
promoter and up-regulated the expression level of NGX6
mRNA, whereas knock-down of Egr-1 reduced endogen-
ous mRNA expression of NGX6 gene in SW480 cells.
From these findings, we conclude that Egr-1 is indeed a
positive regulator of NGX6 gene. In previous study, a
series of related experiment has revealed that nuclear
transcription factor Sp1 also positively regulates NGX6promoter transcriptional expression [13]. Egr-1 binding
may influence the occupancy of Sp1 proteins in certain
environment such as hypoxia [15] and result in the induc-
tion of NGX6 gene expression changes. Further studies
needs to be done to confirm this hypothesis.
Conclusions
In summary, the current study provides a molecular
model for Egr-1 in positive regulation of NGX6 promoter
activity and mRNA expression. These results will help to
better understand the role of NGX6 gene in carcinoma
progression and may provide a new potential therapeutic
target for cancer therapy from the view of knockdown of
Egr-1 and down-regulation of NGX6 gene.
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